Peer-reviewed veterinary case report
Paclitaxel treatment helps shrink mast cell tumors in dogs
By Rivera, P et al.·Published in The Journal of small animal practice·2013·Department of Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
- Species:
- dog
Plain-English summary
A group of 29 dogs with mast cell tumors, which can cause lumps and skin issues, were treated with a new chemotherapy drug called Paccal Vet. After three treatments, about 59% of the dogs showed improvement in their tumors, and most maintained or improved their quality of life. While some dogs experienced temporary side effects like low white blood cell counts, the treatment was generally safe. Unfortunately, a few dogs did not survive due to the progression of their disease. Overall, Paccal Vet seems to be a promising option for treating these tumors in dogs.
People also search for: dog mast cell tumor treatment · Paccal Vet for dogs · mast cell tumor symptoms in dogs
Abstract
OBJECTIVE: To determine the clinical efficacy and safety of a cremophor-free formulation of paclitaxel (Paccal Vet, Oasmia Pharmaceuticals) in dogs with mast cell tumours. METHODS: Paccal Vet was administered at a median dose of 145 (range, 135 to 150) mg/m(2) intravenously once every 21 days for three cycles to 29 dogs with macroscopic grade 2 or 3 mast cell tumour. Efficacy was assessed by tumour response (Response Evaluation Criteria in Solid Tumours version 1.0) and performance status score. Progression-free survival, quality of life and safety/adverse events were also evaluated. Clinical safety was assessed by clinicopathological analyses and recording of adverse events. RESULTS: Complete or partial response was observed in 59% of dogs. Performance status score remained constant or improved for 20 dogs and decreased by one grade for 9 dogs. Median time to progression was 247 (range, 42 to 268) days. Expected, transient frequently subclinical adverse events (primarily grade 3/4 neutropenia and grade 1/2 leukopenia) were observed in the majority of dogs. Nine dogs were euthanased and one dog died due to disease progression. CLINICAL SIGNIFICANCE: Paccal Vet appears to be a clinically safe and effective treatment for canine mast cell tumours. Further controlled confirmatory investigation is warranted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23190121/